# 

# 

# 

# 

# 



## 

|Contents|||||~Pa e|
|---|---|---|---|---|---|
|Reference|and Administrative|||Details ofthe Charity|3 —4|
|Trustee's|Report||||5-22|
|Statement|ofTrustee's||responsibilities||23|
|Independent<br>auditor's||report|||24 - 27|
|Foreword|||||28|
|Statement|of Financial||Activities||29|
|Balance Sheet|||||30|
|Statement|of Cashflow||||31|
|Statement|ofAccounting||Policies||32 - 36|
|Notes to the Financial||Statements|||37-45|





# 

## 

## 

## 

## 



## 

## 

## 



## 

## 

## 

## 

## 

## 

## 



## 

## 

## 

## 

## 

|mbers|durin<br>the<br>e|rlod A<br>ril 202|1 to Janua<br>2023'|||
|---|---|---|---|---|---|
|Ngozi|Lyn Cole|Chair||||
|David|Barnes|Non-Executive<br>Director - retired 31 March 2022||||
|Hayley Wardle||Executive|Director of Finance from|1 April 2021||
|Melanic Johnson||Executive|Director of Nursing,<br>Midwifery<br>and AHPs|||
|Anita Hagon||Sunderland|Public Constituency<br>to|30June 2021 and||
|||reappointed|as Council of Governor|Representative|from|
|||September|2022|||
|Karen|White|South Tyneside<br>Public Constituency||to June 2022||
|Joyce|Welsh|South Tyneside<br>Public Constituency||from 1 October||
|||2021 until|August 2022|||
|Roy McLachlan||Non-Executive<br>Director - from 15August 2022||||
|Martin|Knowles|Non-Executive<br>Director - from 15August 2022||||
|Angela|Thompson|Council of|Governor Representative|from September||
|||2022||||



## 

## 



## 



## 

## 

## 



## 

## 

## 

## 



## 



## 

## 



## 

## 



## 

## 



## 

## 

## 

## 

## 



## 



## 

## 

## 

## 

## 

## 

## 



## 

## 

## 

## 

## 




## 

## 



## 

## 



## 

## 

## 



## 







## 

## 

## 

## 

## 



## 

## 

## 

## 



## 

## 



## 

## 

## 

## 



## 

## 

## 

## 



## 

|||||||Total|Total|
|---|---|---|---|---|---|---|---|
|||Notes|Unrestricted|Restricted|Endowment|2022|2021|
||||Funds|Funds|Funds|Funds|Funds|
||||EOOO|f000|EOOO|KOOO|EOOD|
|Income from:||||||||
|Donations<br>&Legaoes|||2,346||0|2,349|1,567|
|Grants||2.4||70||70|258|
|Charitable<br>Activities|||92|||92|69|
|Other Trading<br>Activities||||||||
|Investments||9,3|77|||81|83|
|Total Income|||2,523|75|0|2,598|1,983|
|Expenditure<br>on:||||||||
|Raising Funds|||(56)||0|(59)|(24)|
|Charitable<br>Activities|||(1,121)|(72)|0|(1,193)|(824)|
|Total Expenditure||7|(1,170)|(73)|0|(1,252)|(846)|
|Net Gain on investments||9.1|79|8|0|87|412|
|Net Income I(Expenditure)|||1,423|10|0|1,433|1,547|
|Transfer between<br>funds|||0|0|0|0|0|
|Net movement<br>in funds|||1,423|10|0|1,433|1,547|
|Reconciliation<br>ofFunds:||||||||
|Total funds brought|forward||6,796|167|159|7,122|5,575|
|Total funds carried forward||13|8,219|177|159|8,555|7,122|





## 

|||||||Total|Total|
|---|---|---|---|---|---|---|---|
||Notes|Unrestricted|Restricted|Endowment||2022|2021|
|||Funds|Funds|Funds||Funds|Funds|
|||6000|6000|6000||6000|6000|
|Non currant assets||||||||
|Investments|9.1,9.2|3,648|142|0||3,790|3713|
|Total non-current<br>assets||3,648|142|0||3,790|3,713|
|Current assets||||||||
|Trade and other receivables|10|35||0||35|27|
|Cash and cash equivalents||5,109|105|159||5,373|3,531|
|Total current assets||5,144|105|159||5,408|3,558|
|Current<br>liabilities||||||||
|Trade and other payables|12|(573)|(70)|0||(643)|(149)|
|Net current assets||4,571|35|159||4,765|3,409|
|Total net assets||8,219|177|159|.|8,555|7,122|
|Retained funds ofthe Charity||||||||
|Endowment<br>Funds<br>Restricted<br>Income Funds<br>Unrestricted<br>Income Funds|13.1<br>13.3<br>13.5|0<br>0<br>8,219|0<br>177<br>0|159<br>0<br>0||159<br>177<br>8,219|159<br>167<br>6,796|
|Total retai'ned<br>funds ofthe Charity||8,219|177|159||8,555|7,122|





## 

||||||(Restated)|
|---|---|---|---|---|---|
||||Year Ended||Year Ended|
||||31 March 22|.|31 March 21|
||||f'000s||E'000s|
|Net income and expenditure<br>for the reporting||period|1,433||1,547|
|(Increase)/Decrease<br>in current debtors|||(8)||5|
|Investment<br>income received|||(81)||(83)|
|Net Gain on investments<br>revaluation|||(87)||(412)|
|Increase<br>/ (Decrease) in current creditors|||494||(598)|
|Net cash inflow/(ouNow)|from operating|activities|1,751||459|
|Disposal at sale proceeds|values||219||677|
|Acquisitions<br>at cost|||(209)||(716}|
|Investment<br>income received|||81||83|
|Net cash inflow/(outflow)|from investment|activities|91||44|
|Net cash inflow/(outflow)|cash and cash|equivalents|1,842||503|
|Cash and cash equivalents|at beginning|ofthe period|3,531||3,028|
|Cash and cash equivalents|at end ofthe|period|5,373||3,531|





## 


## 


## 

## 



## 

## 

## 

## 

## 

## 

## 



## 

## 

## 

## 

## 

## 

## 

## 



## 

## 

## 

## 

## 



## 

## 

## 

## 

## 

## 



## 

|Income from|Income from|2||||||||Tt(tat|Total|
|---|---|---|---|---|---|---|---|---|---|---|---|
|donations|tt||||||Unrestricted|Restricted|Endowment|2022|2021|
|legacies|||||||Funds<br>f000|Funds<br>f000|Funds<br>,f000|Funds<br>f000|Funds<br>f000|
|||2.1|Donations|||||||||
||||Donations|from individuals|||213|||214|162|
||||Donations|from charities|||4|||4|24|
||||Corporate|donations|||2,016|||2,016|1,265|
||||Non corporate donations||||12|||12|6|
||||||||2,245|||2,246|1,457|
||||Analysis ofdonations|||from individuals|f000|received|Number ofdeposits|||
||||||||2022|2021|2022|2021||
||||Individuals|giving|&f1k||78|38|26|16||
||||Individuals|giving|&f100||78|67|249|211||
||||Fundraising|- voluntary||(not via STSFT)|50|21|14|50||
||||Other||||8|36|200|363||
||||Totals||||214|162|489|640||
|||||||||||Total|Total|
||||||||Unrestricted|Restricted|Endowment<br>'|2022|2021|
||||||||Funds|Funds|Funds|Funds|Funds|
||||||||f000|f000|f000|f000|f000|
|||2.2|Legacies|||||||||
||||Rehab and|Elderly|Medicine||0|||0|40|
||||Medical Specia0ies||||100|||100|42|
||||Ophthalmology||||3|||3|22|
||||CardioThoracic<br>Medicine||||0|||0|4|
||||General Purposes||||0|||0|2|
||||||||103||0|103|110|



||Medical Specia0ies<br>Ophthalmology<br>CardioThoracic<br>Medicine<br>General Purposes<br>100<br>3<br>0<br>0<br>103|Medical Specia0ies<br>Ophthalmology<br>CardioThoracic<br>Medicine<br>General Purposes<br>100<br>3<br>0<br>0<br>103|Medical Specia0ies<br>Ophthalmology<br>CardioThoracic<br>Medicine<br>General Purposes<br>100<br>3<br>0<br>0<br>103|Medical Specia0ies<br>Ophthalmology<br>CardioThoracic<br>Medicine<br>General Purposes<br>100<br>3<br>0<br>0<br>103||100<br>3<br>0<br>0<br>0<br>103|100<br>3<br>0<br>0<br>0<br>103|42<br>22<br>4<br>2<br>110|
|---|---|---|---|---|---|---|---|---|
||In total 6 legades were received during 2021/22, ofwhich 2 are residuary||||sums|received re prior years|||
||(2021/22: 10).||||||||
|2.3|Total donations<br>and legacies||2,348|||0|2,349|1,567|
||||||||Total|Total|
||||Unrestricted|Restricted||Endowment|2022|2021|
||||Funds|Funds||Funds|Funds|Funds|
|2.4|Grants||fOOO|f000||f000|f000|f000|
||Grants from Charities||||||||
||Red Sky Foundation||||70||70|0|
||NHS CT - NHS Charities Together||||0||0|198|
||CHSA —Covid19 Healthcare|Support Appeal|||0||0|00|
||||||||70|258|





## 

|Income from||3|||||Total|Total|
|---|---|---|---|---|---|---|---|---|
|charitable||||Unrestricted|Restricted|Endowment|2022|2021|
|activities||||Funds<br>f000|Funds<br>f000|Funds<br>f000|Funds<br>'6000|Funds<br>f000|
||||Course end conference fees|92|||92||
||||8different course types were held (2021/22: 6).||||||
|Income from||4|||||Total|Total|
|other trading|.|||Unrestricted|Restricted|End&a/rment|2022|2021|
|activities||||Funds|Funds|Funds|Funds|Funds|
|||||f000|f000|f000|6000|f000|
||||Staff lottery|6 i|0||||





## 

|Details of|5||||||||||||||Total|Total|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|Fundralslng|||||||||Unrestricted|Restricted|Endowment||||2022|2021|
|expenditure|||||||||Funds|Funds||Funds|||Funds|Funds|
||||||||||f000|f000|||f000||5000|f000|
|||Bought-in services from|||NHS||||(35)|0|||||(35)|(2)|
|||Investment|Broker fee||||||(19)|(1)|||||(20)|(19)|
|||Corporate<br>Fundraising|||non pay||||(4)|0|||||(4)|(3)|
||||||||||(58)|(1)||||9|(59)|(24)|
|||AI traded investment||business||covering|all funds is handled|||by the Charity's|investment||broker, Rathbone<br>Investment||||
|||Management|Ltd.||||||||||||||
|||Bought-in services relate to salary recharges<br>from STSFTin respect ofmanaging<br>equivalent)<br>and the corporate<br>charity fundraiser<br>postf33k (075wte - leaver end||||||||||the staff <br> December||lottery 52k (0.09wte- whole<br>tirr<br> 2021).|||
|Oetags of|||||||||||||||Total|Total|
|Charitable|||||||||Unrestncted|Restricted|Endowment||||2022|2021|
|activities|||||||||Funds|Funds||Funds|||Funds|Funds|
|expenditure|6.1|Cost ofChantable<br>Activities|||||||f000|f000|||f000||f000|f000|
|||Patients'<br>welfare and||amemtie's|||||(238)|0|||||(238)|(231)|
|||Course and|conference||costs||||(65)|0|||||(65)|(39)|
|||Contributions|to NHS||||||(574)|P2)|||||(648)|(464)|
|||Staff welfare|and amenities||||||(176)|0|||||(176)|(41)|
|||Support and|governance||costs||||(66)|0|||||(88)|(49)|
||||||||||(1,121)|P2)||||0|(1,193|(824)|
|Analysis of|6.2|||||Staff / Patient|||Course and||||||Tots I|Total|
|support costs||||||Welfare|and||Conference|Governance|||||2022|2021|
|expenditure||||||Amenities|||Costs|Costs||Research|||Funds|Funds|
|||Support and|governance||cost|f000|||f000|f000||f000|||5000|f000|
|||Unrestricted|||||(42)||(6)|(19)|||||(87)|(49)|
|||Restricted|||||0||0|(1)|||||(1)|0|
||||||||42)||6)|(20)||||0|(68)|(49)|





## 

|Analysis of|7|||||Investment|Costs of||||
|---|---|---|---|---|---|---|---|---|---|---|
|total|||||Costs of|Management|Charitable|Governance|Total|Total|
|expenditure|||||Fundraising|Costs|Activities|Costs|2022|2021|
||||||5000|5000|f000|5000|5000|5000|
|||Other|||(4)|0|(896)|0|(900)|(650)|
|||Bought-in services||from NHS|(35)|0|(273)|(3)|(311)|(163)|
|||Investment<br>Broker fee|||0|(20)|0|0|(20)|(18)|
|||Audit|fees - internal|audit|0|0|(4)|0|(4)|0|
||||provision||||||||
|||Audit|fees - external|statutory|||||(17)|(17)|
||||audit provision||||||||
||||||(39)|(20)|(1,173)|(20)|(1,252)|(848|





## 

|||||||2022|2021|
|---|---|---|---|---|---|---|---|
|||||||Total|Total|
|||||||f000|f000|
|Managed<br>Porffolios||||||||
|Market value at|1 April|||||2,570|2,104|
|Less: Disposals|at|Sales|Proceeds||values|(219)|(677)|
|Add: Acquisitions|at cost|||||209|716|
|Net unrealised<br>and||realised gain||/ (loss) on sale and revaluation||169|427|
|Market value at|31|March||||2,729|2,570|
|Fixed Interest Fund|Holding|||||||
|Market value at|1 April|||||1,143|1,158|
|Lese: Disposals|at|Sales|Proceeds||values|0|0|
|Add: Acquisitions|st cost|||||0|0|
|Net unrealised<br>and||realised gain||/ (loss) on sale and revaluation||82|15|
|Market value at|31|March||||1,081|1,143|
|Total non current asset Investments||||||3,790|3,713|
|Historic cost at 31 March-Managed|||||Porffolios and Fixed Interest Holding|4,221|4,139|
|Traded Non Current Asset Investments:||||||31March|31 March|
|||||||2022|2021|
|||||||Total|Total|
|||||||8000|f000|
|nveshneiits<br>Octad||n|is||Sto k Exchan s|||
|In the UK||||||2,045|2,091|
|Outside the UK||||||183|60|
|Unlisted<br>securities:||||||||
|In Ihe UK||||||1,050|1,041|
|Outside the UK||||||512|521|
|Total||||||3,790|3,713|
|Total gross income:||||||2022|2021|
|||||||Total|Total|
|||||||f000|f000|
|Invastmerits<br>listed on a reco nised|||||Stock Exchan e'|||
|In the UK||||||62|65|
|Outside the UK||||||0|0|
|Unlisted<br>secor/ties:||||||||
|In the UK||||||11|11|
|Outside the UK||||||8|6|
|Investments<br>in a|Common||Deposit||Fund|||
|Current account|/ short term interest|||||||
|Total||||||81|83|




## 



## 

|Analysis of|10|Amounts<br>falling due within|one year:|one year:|||||31 March||31 March|
|---|---|---|---|---|---|---|---|---|---|---|---|
|Trade and other|||||||||2022||2021|
|Receivables|||||||||5000||8000|
|||Trade receivables|||||||9||11|
|||Amounts<br>due from STSFT|||||||1||1|
|||Prepayments<br>and accrued||income|||||25||15|
|||Total receivables<br>falling|due|within|one year||||35||27|
|Analysis of|11|Cash and cash equivalents|||||||$1 INarch||31 March|
|Cash and Cash|||||||||2022||2021|
|Equivalents|||||||||f000||6000|
|||Cash at commercial<br>bank and GBS|||||||4,849||2,997|
|||Notice Deposits (less than||3months)|||||463||463|
|||Cash held<br>in dealing account with|||Investment|Broker|||61||71|
|||Total cash and cash equivalents|||||||5,373||3,531|
|Analysis of|12|Amounts<br>falling due within|one year:||||||31 March||31 March|
|Trade and other|||||||||2022||2021|
|Payables|||||||||'8000||2000|
|||Amounts<br>due to STSFT|||||||(583)||(85)|
|||Trade payablas|||||||(49)||(30)|
|||Accruals and deferred|income||||||11|||
|||Total payables<br>falling due within one year|||||||(643)||(149)|
|Analysis of|13|||||||||||
|Funds||||||||||||
||13.1|Endowment<br>Funds|Balance||||||||Balance|
|Details of||||1 April|||||Gains on|Gains on|$1 March|
|material||||2022|Income||Expenditure|Transfers|Disposals|Revaluations|2022|
|funds-||||8000|FOOO||8000|8000|8000|6000|8000|
|Endowment||||||||||||
|Funds||Fund 1910Legacy<br>Fund 1900Legacy||157'2||||0<br>0|0<br>0||157<br>2|
|||Funds1920-1940 Gifts||1||||0|0||1|
|||Total||159||0|0|0|0|0|159|





## 

|NOTES TO|THE FINANCIAL STATE|THE FINANCIAL STATE|MENTS|(CON|TINUE|D)|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|Analysis of|13(Continued)||||||||||||||||
|Funds|||||||||||||||||
|Detaifa of|13.3|Restricted Funds||||Balance||||||||||Balance|
|material||||||1 April||||||||Gains on|Gain on|31March|
|funds-||||||2022|Income|Expenditure|||Transfers|||Dispossls|Revaluation|2022|
|Restricted||||||f000|f000|||EOOO|||f000|f000|EOOO|f000|
|Funds||Idaterial funds|||||||||||||||
|||Leukaemia<br>Research|Legacy|||97|5|||(2)||||||107|
|||Orthopaedics<br>bequest||||35|0|||0||||||36|
|||Neonatal<br>Unit Legacy||||13|0|||0||||||13|
|||Other designated<br>funds||||22|70|||(71)||||||21|
|||Total|||||70|||P3|||||||
||13.4|Description<br>offunds|||||||||||||||
|||Leukaemia<br>Research|Legacy||||For leukaemis|and||lymphoma|research.||||||
|||Orthopsedics<br>bequest|||||For the provision||ofan operating|||theatre||bed specifically designed|||
||||||||for people suffering|||from curvature|||ofthe|spine|||
|||Neonatal<br>Unit legacy|||||For South Tynesids|||neonetes|||||||
|Details of|13.5|Unrestricted<br>Funds|||||||||||||||
|material||||||Balance||||||||||Balance|
|funds-||||||1 April||||||||Net Gain on|Net Gain on|31March|
|Unrestrlcted||||||2022|Income|Expenditure|||Transfers|||Disposals|Revaluation|2022|
|Funds||||||. f000|f000|||EOOO|||f000|EOOO|EOOO|EOOO|
|||Material funds|||||||||||||||
|||Medical Equipment|purposes|||1618|2,021|||(330)|||0|24||3,333|
|||NeoNatal<br>Unit||||315|82|||(7)|||0|4||394|
|||COVID 19||||536|6|||(209)|||0|8||339|
|||Paediatric department||||335|6|||P)|||0|4||330|
|||General Purposes||||430|35|||(153)|||0|5||317|
|||Rise Above Cancer||||181|29|||(42)|||0|2||170|
|||SRH ICCU||||47|111|||(I)|||0|1||150|
|||Glaucoma<br>purposes||||153|2|||(10)|||0|2||147|
|||Maternity<br>Unit||||138|2|||(2)|||0|2||140|
|||SRH Coronary<br>Care||||167|4|||(99)|||0|2||74|
|||Phoenix Unit - Chemotherapy||||111|17|||1|||0|2||131|
|||Clinical<br>Haemstology||||123|5|||(11)|||0|2||119|
|||SEIGeneral Purposes||||104|10|||(60)|||0|3||57|
|||Diabetes purposes|Legacy|||09|1|||(I)|||0|1||90|
|||Renal purposes||||74|14|||(1)|||0|1||88|
|||SRH Ward D45 Stroke (prev||ESB,D41)||89|5|||(8)|||0|1||87|
|||Pharmacy<br>department||||75|6|||&1)|||0|1||01|
|||Orthopaedic<br>Department||||66|2|||(16)|||0|1||73|
|||SIDH Cardiology<br>bequests||||65|1|||O)|||0|1||66|
|||South Tyneside<br>Community||Planned|Car|58|10|||&3)|||0|0||65|
|||Raif Lottery||||62|12|||(11)|||0|1||64|
|||ENT/SALT purposes||||61|1|||O)|||0|I||62|
|||ALS course - resuscitation||||45|49|||(33)|||0|I||62|
|||Elderly Medicine wards||||75|1|||(16)|||0|1||59|
|||SRH Cardiology||||57|1|||(1)|||0|I||58|
|||Gynaecology<br>purposes||||54|1|||(3)|||0|0||52|
|||Thoradc Medicine||||50|2|||(1)|||0|1||52|
|||Other||||1598|87|||(150)|||0|0||1,543|
|||Total Unrestricted|Funds|||0,796|2,523|||1,179)|||0|71|8|0,219|





## 




## 

## 

## 

## 


## 

## 

##